ERBB2 and gastroesophageal junction adenocarcinoma: Another phase II trial (NCT05702229) is investigating AZD2936, a bispecific antibody targeting both PD - 1 and TIGIT, in combination with FOLFOX or XELOX as first-line therapy for HER2-negative unresectable or metastatic gastric or GEJ adenocarcinoma.